Screening strategy for non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of stea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2023-02-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2022-0336.pdf |
| _version_ | 1797871537076830208 |
|---|---|
| author | Saisai Zhang Lung-Yi Mak Man-Fung Yuen Wai-Kay Seto |
| author_facet | Saisai Zhang Lung-Yi Mak Man-Fung Yuen Wai-Kay Seto |
| author_sort | Saisai Zhang |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liverrelated complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening. |
| first_indexed | 2024-04-10T00:45:26Z |
| format | Article |
| id | doaj.art-c95792926bb943369b1793d7994b9a52 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-04-10T00:45:26Z |
| publishDate | 2023-02-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-c95792926bb943369b1793d7994b9a522023-03-14T01:46:51ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-02-0129SupplS103S12210.3350/cmh.2022.03361737Screening strategy for non-alcoholic fatty liver diseaseSaisai Zhang0Lung-Yi Mak1Man-Fung Yuen2Wai-Kay Seto3 Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong KongNon-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liverrelated complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.http://e-cmh.org/upload/pdf/cmh-2022-0336.pdfnafldmetabolic diseasesdiabetes mellitusfatty liverfibrosis |
| spellingShingle | Saisai Zhang Lung-Yi Mak Man-Fung Yuen Wai-Kay Seto Screening strategy for non-alcoholic fatty liver disease Clinical and Molecular Hepatology nafld metabolic diseases diabetes mellitus fatty liver fibrosis |
| title | Screening strategy for non-alcoholic fatty liver disease |
| title_full | Screening strategy for non-alcoholic fatty liver disease |
| title_fullStr | Screening strategy for non-alcoholic fatty liver disease |
| title_full_unstemmed | Screening strategy for non-alcoholic fatty liver disease |
| title_short | Screening strategy for non-alcoholic fatty liver disease |
| title_sort | screening strategy for non alcoholic fatty liver disease |
| topic | nafld metabolic diseases diabetes mellitus fatty liver fibrosis |
| url | http://e-cmh.org/upload/pdf/cmh-2022-0336.pdf |
| work_keys_str_mv | AT saisaizhang screeningstrategyfornonalcoholicfattyliverdisease AT lungyimak screeningstrategyfornonalcoholicfattyliverdisease AT manfungyuen screeningstrategyfornonalcoholicfattyliverdisease AT waikayseto screeningstrategyfornonalcoholicfattyliverdisease |